CD33 and acute myeloid leukemia: Importantly, a phase I study at the Chinese PLA General Hospital (ClinicalTrials.gov number, NCT01864902) used lentivirally transduced anti-CD33-41BBζ CAR T cells delivered in escalating fractions to a single patient with refractory AML, which resulted in a transient response [67].